Conflict of interest statement: The following represents disclosure information 
provided by authors of this manuscript. All relationships are considered 
compensated. Relationships are self-held unless noted. I = Immediate Family 
Member, Inst = My Institution. Relationships may not relate to the subject 
matter of this manuscript. For more information about ASCO's conflict of 
interest policy, please refer to www.asco.org/rwc or 
ascopubs.org/po/author-center. BENEDITO A. CARNEIRO: Consulting or Advisory 
Role: Bristol-Myers Squibb, Bayer HealthCare Pharmaceuticals KATHARINE ANN 
COLLIER: No relationship to disclose REBECCA J. NAGY: Employment: Guardant 
Health Stock and Other Ownership Interests: Guardant Health SAHITHI PAMARTHY: No 
relationship to disclose VINAY SAGAR: No relationship to disclose STEPHEN 
FAIRCLOUGH: Employment: Guardant Health Stock and Other Ownership Interests: 
Guardant Health Research Funding: Guardant Health Patents, Royalties, Other 
Intellectual Property: Guardant Health Travel, Accommodations, Expenses: 
Guardant Health JUSTIN ODEGAARD: Employment: Guardant Health Stock and Other 
Ownership Interests: Guardant Health RICHARD B. LANMAN: Employment: Guardant 
Health, Veracyte Leadership: Guardant Health Stock and Other Ownership 
Interests: Guardant Health Research Funding: Guardant Health RICARDO COSTA: No 
relationship to disclose TIMOTHY TAXTER: Employment: Tempus Stock and Other 
Ownership Interests: Tempus TIMOTHY M. KUZEL: Honoraria: Genentech/Roche, 
Celgene, Eisai, Argos Therapeutics, Amgen, Astellas Pharma, Bristol-Myers 
Squibb, Medivation, Exelixis, AbbVie, Merck Consulting or Advisory Role: CVS, 
Kyowa Hakko Kirin, Stemline Therapeutics Speakers’ Bureau: Celgene, 
Genentech/Roche, Astellas Pharma, Medivation Research Funding: Genentech/Roche 
(Inst), Eisai (Inst), Bristol-Myers Squibb (Inst) Travel, Accommodations, 
Expenses: Genentech, Celgene, Astellas Pharma, Argos Therapeutics, Medivation, 
Amgen, Kyowa Hakko Kirin, Merck, Stemline Therapeutics ALICE FAN: Stock and 
Other Ownership Interests: Molecular Decisions Consulting or Advisory Role: 
Verily Research Funding: Calithera Biosciences Patents, Royalties, Other 
Intellectual Property: Stanford Patent has been licensed YOUNG KWANG CHAE: 
Consulting or Advisory Role: Foundation Medicine, Boehringer Ingelheim, 
Biodesix, Counsyl, AstraZeneca, Guardant Health, Speakers’ Bureau: Merck, 
Genentech/Roche Travel, Accommodations, Expenses: Hanmi MASSIMO CRISTOFANILLI: 
Honoraria: Dompé Farmaceutici, Pfizer Consulting or Advisory Role: Dompé 
Farmaceutici, Newomics, Vortex Biosciences MAHA H. HUSSAIN: Honoraria: Onclive, 
Sanofi Research Funding: Genentech (Inst), Pfizer (Inst), PCCTC (Inst), 
AstraZeneca (Inst) Patents, Royalties, Other Intellectual Property: Title: 
Systems and methods for tissue imaging, 3676 our file, serial No. 
UM-14437/US-1/PRO 60/923,385UM-14437/US-2/ORD 12/101,753US 8,185,186 (US patent 
No.), Systems and methods for tissue imaging (issued patent) EP 08745653.9 (EP 
application No.), Systems and methods for tissue imaging (pending) CA 2683805 
(Canadian application No.), Systems and methods for tissue imaging (pending) US 
13/362,500 (US application No.), Systems and methods for tissue imaging 
(continuation application of US 8,185,186); Method of treating cancer, docket 
No., serial No. 224990/10-016P2/311733 61/481/671, application filed on February 
5, 2011; Dual inhibition of MET and VEGF for the treatment of castration 
resistant prostate cancer and osteoblastic bone metastases, 
applicant/proprietor: Exelexis, application No./patent No. 11764665.4- 1464, 
application No./patent No. 11764656.2-1464, application filed on September 26, 
2011 Travel, Accommodations, Expenses: Sanofi SARKI A. ABDULKADIR: Stock and 
Other Ownership Interests: Vortex Therapeutics Patents, Royalties, Other 
Intellectual Property: Patent pending through Northwestern University for new 
MYC inhibitors FRANCIS J. GILES: Employment: Actuate Leadership: Actuate 
Honoraria: Novartis Consulting or Advisory Role: Novartis Travel, 
Accommodations, Expenses: MedImmune, Novartis, Foundation Medicine